Fifty-seven patients with MAGE-3-positive measurable metastatic cancer, most of them with melanoma, were vaccinated with escalating doses of a recombinant MAGE-3 protein combined with a fixed dose of the immunological adjuvant SBAS-2, which contained MPL and QS21. The immunisation schedule included 4 intramuscular (i.m.) injections at 3-week intervals. Patients whose tumour stabilised or regressed after 4 vaccinations received 2 additional vaccinations at 6-week intervals. The vaccine was generally well tolerated. Among the 33 melanoma patients who were evaluable for tumour response, we observed 2 partial responses, 2 mixed responses and 1 stabilisation. Time to progression in these 5 patients varied from 4 to 29 months. In addition, a partial response lasting 10 months was observed in 1 of the 3 metastatic bladder cancer patients included. None of the tumour responses described above involved visceral metastases. Immunological responses to the vaccine will be reported separately.

Additional Metadata
Keywords Antibodies, Cancer, Immunological adjuvant SBAS-2, Immunotherapy, MAGE-3 protein, Melanoma, T lymphocyte
Persistent URL,
Journal European Journal of Cancer
Marchand, M.A, Punt, C.J.A, Aamdal, S, Escudier, B, Kruit, W.H.J, Keilholz, U, … Stoter, G. (2003). Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: A clinical report. European Journal of Cancer, 39(1), 70–77. doi:10.1016/S0959-8049(02)00479-3